Cartesian Growth Corporation III filings document material events and agreements for a blank-check company, including shareholder voting matters, capital-structure disclosures, governance matters, and SPAC security terms. The issuer's Form 8-K disclosures cover the mechanics associated with units, warrants or rights, trust-account arrangements, redemptions, deadline extensions, and shareholder approvals when applicable.
CGCT filings may also include transaction-related operating, financial, clinical, or regulatory information alongside the SPAC-focused disclosures that describe the issuer's securities, voting framework, and public-company obligations.
Cartesian Growth Corporation III, a SPAC, reported net income of $1.68 million for the quarter ended March 31 2026, driven by $2.49 million of interest on its Trust Account and offset by $0.81 million of general and administrative costs.
Total assets were $286.4 million, including $285.87 million of investments in the Trust Account backing the 27,600,000 Class A shares subject to redemption at about $10.36 per share. Cash outside the trust was $396,210, and the company had a working capital deficit and disclosed substantial doubt about its ability to continue as a going concern absent a business combination.
The SPAC has a pending Business Combination Agreement with Factorial Inc., alongside a planned $100 million PIPE financing for 9,927,184 shares of New Factorial Series A Common Stock, and expects the transaction to close in mid‑2026, subject to shareholder approvals and customary conditions.
Cartesian Growth Corp III reports that Meteora Capital, LLC and Vik Mittal disclosed beneficial ownership of 1,492,978 shares of Class A Common Stock, representing 5.40% of the class. The filing lists shared voting and shared dispositive power over these shares.
The statement is signed by Vik Mittal on 05/15/2026 and provides the reporting persons' business address in Boca Raton, Florida.
Cartesian Growth Corporation III filed a Form 8-K reporting that the joint Form S-4 for the proposed business combination with Factorial Inc. was declared effective by the SEC on May 6, 2026. An extraordinary general meeting of Cartesian III shareholders is scheduled for May 27, 2026 to vote on the transaction.
The release states Cartesian III holds approximately $287 million in trust and, assuming no redemptions, the transaction would imply a pro forma equity value of approximately $1.5 billion, which includes an expected $100 million common equity PIPE. The parties anticipate closing in June 2026, subject to satisfaction of closing conditions and shareholder approval.
Cartesian Growth Corporation III reported that its joint registration statement on Form S-4 with Factorial Inc., covering their proposed business combination, was declared effective by the SEC on May 6, 2026. This clears a key regulatory step toward closing the transaction.
The extraordinary general meeting of Cartesian III shareholders to vote on the deal is scheduled for May 27, 2026$287 million in cash in trust, and the transaction is expected to create a combined company with a pro forma equity value of about $1.5 billion, including an anticipated $100 million common equity PIPE investment, assuming no redemptions.
Cartesian Growth Corporation III: Schedule 13G filed reporting 1,504,842 Class A Ordinary Shares (5.5%). Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report shared voting and dispositive power over 1,504,842 shares of Class A Ordinary Shares (CUSIP G19307100) as shown on the cover page.
The holders filed a Joint Filing Agreement dated May 6, 2026 and state the shares are held by entities overseen by Millennium-related managers; the filing disclaims that this statement alone establishes beneficial ownership.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC report shared beneficial ownership of 362,963 shares (Class A Ordinary Shares, par value $0.0001) of CARTESIAN GROWTH CORP III. The cover data lists this as 1.3% of the class. The filing is a joint Schedule 13G/A amendment that attributes the securities to Goldman Sachs reporting units and explains subsidiary/parent relationships under Item 7 and exhibits.
The filing notes standard disclaimers about client accounts and certain investment entities and is signed by an attorney-in-fact on behalf of both filers.
Cartesian Growth Corporation III (CGC) filed an amendment to a Form S-4 to combine with Factorial Inc. via a domestication to Delaware, a merger and related transactions (the "Business Combination"). The filing describes the Consideration Ratio mechanics tied to an $1,100,000,000 Equity Value, a PIPE for approximately $100,000,000 (9,927,184 shares) and registration of up to 143,912,243 shares, up to 16,200,000 warrants and underlying shares.
The Domestication, Merger, Sponsor agreements, lock-ups, registration rights and redemption procedures are detailed, including a Maximum Redemptions Scenario (assumed 27,600,000 redemptions at an illustrative $10.30 per share) and estimated post-closing ownership and voting power breakdowns for Sponsor, Factorial Founders and PIPE Investors. The proxy/prospectus emphasizes closing conditions, Nasdaq listing requirements, and related governance and dilution matters.
CARTESIAN GROWTH CORPORATION III: Picton Mahoney Asset Management reports beneficial ownership of 1,300,000 Class A ordinary shares, representing 4.71% of the class. The filing cites a shares outstanding figure of 27,600,000 as of March 18, 2026.
Factorial Inc. announced the appointment of Dr. Dieter Zetsche to the Board of Directors upon closing of its previously announced business combination with Cartesian Growth Corporation III. The filing states Dr. Zetsche has been an early investor and advisor since 2021 and will support the company’s commercial scaling and public market transition.
The release highlights Dr. Zetsche’s leadership experience at Daimler AG and Chrysler, and notes Factorial’s partnerships and technical milestones, including Mercedes‑Benz road testing exceeding 1,200 km on a single charge and Stellantis lab validation of 77 Ah cells.